Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Diseases

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 53 articles:
HTML format



Single Articles


    November 2022
  1. WUESTEFELD A, Iakovleva V, Yap SXL, Ong ABL, et al
    A pro-regenerative environment triggers premalignant to malignant transformation of senescent hepatocytes.
    Cancer Res. 2022 Nov 30:CAN-22-1477. doi: 10.1158/0008-5472.CAN-22-1477.
    PubMed     Abstract available


  2. ZHU X, Song G, Zhang S, Chen J, et al
    Asialoglycoprotein Receptor 1 Functions as a Tumor Suppressor in Liver Cancer via Inhibition of STAT3.
    Cancer Res. 2022;82:3987-4000.
    PubMed     Abstract available


    October 2022
  3. DUDA DG, Jain RK
    Revisiting Antiangiogenic Multikinase Inhibitors in the Era of Immune Checkpoint Blockade: The Case of Sorafenib.
    Cancer Res. 2022;82:3665-3667.
    PubMed     Abstract available


    September 2022
  4. XIAO Y, Li Y, Shi D, Wang X, et al
    MEX3C-mediated decay of SOCS3 mRNA promotes JAK2/STAT3 signaling to facilitate metastasis in hepatocellular carcinoma.
    Cancer Res. 2022 Sep 16. pii: 709244. doi: 10.1158/0008-5472.CAN-22-1203.
    PubMed     Abstract available


  5. MAN K, Pang L, Yeung OWH, Ng KTP, et al
    Postoperative plasmacytoid dendritic cells secrete IFN-alpha to promote recruitment of myeloid-derived suppressor cells and drive hepatocellular carcinoma recurrence.
    Cancer Res. 2022 Sep 14. pii: 709225. doi: 10.1158/0008-5472.CAN-22-1199.
    PubMed     Abstract available


  6. HUANG M, Long J, Yao Z, Zhao Y, et al
    METTL1-mediated m7G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma.
    Cancer Res. 2022 Sep 14. pii: 709196. doi: 10.1158/0008-5472.CAN-22-0963.
    PubMed     Abstract available


  7. HU B, Zou T, Qin W, Shen X, et al
    Inhibition of EGFR overcomes acquired lenvatinib resistance driven by STAT3-ABCB1 signaling in hepatocellular carcinoma.
    Cancer Res. 2022 Sep 6. pii: 708982. doi: 10.1158/0008-5472.CAN-21-4140.
    PubMed     Abstract available


    August 2022
  8. BARTON MC, Lozano G
    p53 Activation Paradoxically Causes Liver Cancer.
    Cancer Res. 2022;82:2824-2825.
    PubMed     Abstract available


    July 2022
  9. PRIVES C, Suzuki S, Venkatesh D, Kanda H, et al
    GLS2 is a tumor suppressor and a regulator of ferroptosis in hepatocellular carcinoma.
    Cancer Res. 2022 Jul 27. pii: 707287. doi: 10.1158/0008-5472.CAN-21-3914.
    PubMed     Abstract available


  10. LI Y, Li B, Xu Y, Qian L, et al
    GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors.
    Cancer Res. 2022 Jul 27. pii: 707288. doi: 10.1158/0008-5472.CAN-22-0042.
    PubMed     Abstract available


  11. WANG JC, Chen DP, Lu SX, Chen JB, et al
    PIM2 expression induced by proinflammatory macrophages suppresses immunotherapy efficacy in hepatocellular carcinoma.
    Cancer Res. 2022 Jul 11. pii: 706923. doi: 10.1158/0008-5472.CAN-21-3899.
    PubMed     Abstract available


  12. XIE C, Wang FY, Sang Y, Chen B, et al
    Mitochondrial Micropeptide STMP1 Enhances Mitochondrial Fission to Promote Tumor Metastasis.
    Cancer Res. 2022;82:2431-2443.
    PubMed     Abstract available


    June 2022
  13. MOK EH, Leung CO, Zhou L, Lei MML, et al
    Caspase-3-induced activation of SREBP2 drives drug resistance via promotion of cholesterol biosynthesis in hepatocellular carcinoma.
    Cancer Res. 2022 Jun 29. pii: 705310. doi: 10.1158/0008-5472.CAN-21-2934.
    PubMed     Abstract available


  14. SHAN H, Liu T, Gan H, He S, et al
    RNA helicase DDX24 stabilizes LAMB1 to promote hepatocellular carcinoma progression.
    Cancer Res. 2022 Jun 28. pii: 705275. doi: 10.1158/0008-5472.CAN-21-3748.
    PubMed     Abstract available


  15. MAKINO Y, Hikita H, Fukumoto K, Sung JH, et al
    Constitutive activation of the tumor suppressor p53 in hepatocytes paradoxically promotes non-cell autonomous liver carcinogenesis.
    Cancer Res. 2022 Jun 13. pii: 704882. doi: 10.1158/0008-5472.CAN-21-4390.
    PubMed     Abstract available


    May 2022
  16. HEINZ MC, Peters NA, Oost KC, Lindeboom RGH, et al
    Liver Colonization by Colorectal Cancer Metastases Requires YAP-Controlled Plasticity at the Micrometastatic Stage.
    Cancer Res. 2022;82:1953-1968.
    PubMed     Abstract available


  17. LIU Z, Ye Y, Liu Y, Liu Y, et al
    RNA Helicase DHX37 Facilitates Liver Cancer Progression by Cooperating with PLRG1 to Drive Superenhancer-Mediated Transcription of Cyclin D1.
    Cancer Res. 2022;82:1937-1952.
    PubMed     Abstract available


    April 2022
  18. CHENG Y, Bai F, Ren X, Sun R, et al
    Phosphoinositide-Binding Protein TIPE1 Promotes Alternative Activation of Macrophages and Tumor Progression via PIP3/Akt/TGFbeta Axis.
    Cancer Res. 2022;82:1603-1616.
    PubMed     Abstract available


  19. BAYARD Q, Cordier P, Peneau C, Imbeaud S, et al
    Structure, Dynamics, and Impact of Replication Stress-Induced Structural Variants in Hepatocellular Carcinoma.
    Cancer Res. 2022 Apr 8:OF1-OF12. doi: 10.1158/0008-5472.CAN-21-3665.
    PubMed     Abstract available


    January 2022
  20. LI J, Hu ZQ, Yu S, Mao L, et al
    CircRPN2 inhibits aerobic glycolysis and metastasis in hepatocellular carcinoma.
    Cancer Res. 2022 Jan 19. pii: 0008-5472.CAN-21-1259.
    PubMed     Abstract available


  21. ADACHI Y, Kamiyama H, Ichikawa K, Fukushima S, et al
    Inhibition of FGFR Reactivates IFNgamma Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies.
    Cancer Res. 2022;82:292-306.
    PubMed     Abstract available


    December 2021
  22. MA WK, Voss DM, Scharner J, Costa ASH, et al
    ASO-based PKM splice-switching therapy inhibits hepatocellular carcinoma growth.
    Cancer Res. 2021 Dec 17. pii: 0008-5472.CAN-20-0948.
    PubMed     Abstract available


  23. CHEN Y, Ling Z, Cai X, Xu Y, et al
    Activation of YAP1 by N6-methyladenosine-modified CircCPSF6 Drives Malignancy in Hepatocellular Carcinoma.
    Cancer Res. 2021 Dec 16. pii: 0008-5472.CAN-21-1628.
    PubMed     Abstract available


  24. XU F, Tong M, Tong CSW, Chan BKC, et al
    A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment.
    Cancer Res. 2021;81:6219-6232.
    PubMed     Abstract available


  25. BELLIDO MOLIAS F, Sim A, Leong KW, An O, et al
    Antisense RNAs Influence Promoter Usage of Their Counterpart Sense Genes in Cancer.
    Cancer Res. 2021;81:5849-5861.
    PubMed     Abstract available


    November 2021
  26. PEASE DR, Fernandez-Zapico ME
    mTOR-Dependent ARID1A Degradation: A New Twist in the Genetic-Epigenetic Interplay Driving Hepatocellular Carcinoma.
    Cancer Res. 2021;81:5608-5610.
    PubMed     Abstract available


  27. REN X, Rong Z, Liu X, Gao J, et al
    The protein kinase activity of NME7 activates Wnt/beta-Catenin signaling to promote one-carbon metabolism in hepatocellular carcinoma.
    Cancer Res. 2021 Nov 11. pii: 0008-5472.CAN-21-1020.
    PubMed     Abstract available


  28. SENDI H, Yazdimamaghani M, Hu M, Sultanpuram N, et al
    Nanoparticle delivery of miR-122 inhibits colorectal cancer liver metastasis.
    Cancer Res. 2021 Nov 9. pii: 0008-5472.CAN-21-2269.
    PubMed     Abstract available


    October 2021
  29. BARCENA-VARELA M, Lujambio A
    A Novel Long Noncoding RNA Finetunes the DNA Damage Response in Hepatocellular Carcinoma.
    Cancer Res. 2021;81:4899-4900.
    PubMed     Abstract available


    September 2021
  30. LOH JJ, Li TW, Zhou L, Wong TL, et al
    FSTL1 secreted by activated fibroblasts promotes hepatocellular carcinoma metastasis and stemness.
    Cancer Res. 2021 Sep 22. pii: 0008-5472.CAN-20-4226.
    PubMed     Abstract available


  31. KAN X, Zhou G, Zhang F, Ji H, et al
    Interventional Optical Imaging Permits Instant Visualization of Pathological Zones of Ablated Tumor Periphery and Residual Tumor Detection.
    Cancer Res. 2021;81:4594-4602.
    PubMed     Abstract available


    August 2021
  32. ZHANG S, Zhou YF, Cao J, Burley SK, et al
    mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma.
    Cancer Res. 2021 Aug 24. pii: 0008-5472.CAN-21-0206.
    PubMed     Abstract available


    July 2021
  33. UNFRIED JP, Marin-Baquero M, Rivera-Calzada A, Razquin N, et al
    Long noncoding RNA NIHCOLE promotes ligation efficiency of DNA double-strand breaks in hepatocellular carcinoma.
    Cancer Res. 2021 Jul 28. pii: 0008-5472.CAN-21-0463.
    PubMed     Abstract available


  34. QIU X, Yang S, Wang S, Wu J, et al
    M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma.
    Cancer Res. 2021 Jul 23. pii: 0008-5472.CAN-21-0468.
    PubMed     Abstract available


  35. TANG M, Yang M, Wu G, Mo S, et al
    Epigenetic Induction of Mitochondrial Fission Is Required for Maintenance of Liver Cancer-Initiating Cells.
    Cancer Res. 2021;81:3835-3848.
    PubMed     Abstract available


  36. PARK M, Kim JW, Kim KM, Kang S, et al
    Circulating Small Extracellular Vesicles Activate TYRO3 to Drive Cancer Metastasis and Chemoresistance.
    Cancer Res. 2021;81:3539-3553.
    PubMed     Abstract available


    June 2021
  37. SHRIKI A, Lanton T, Sonnenblick A, Levkovitch-Siany O, et al
    Multiple Roles of IL-6 in Hepatic Injury, Steatosis, and Senescence Aggregate to Suppress Tumorigenesis.
    Cancer Res. 2021 Jun 11. pii: 0008-5472.CAN-21-0321.
    PubMed     Abstract available


  38. GONZALEZ-ROMERO F, Mestre D, Aurrekoetxea I, O'Rourke CJ, et al
    E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment.
    Cancer Res. 2021;81:2874-2887.
    PubMed     Abstract available


  39. LULLI M, Del Coco L, Mello T, Sukowati C, et al
    DNA Damage Response Protein CHK2 Regulates Metabolism in Liver Cancer.
    Cancer Res. 2021;81:2861-2873.
    PubMed     Abstract available


    May 2021
  40. ZHAO Z, Gad H, Benitez-Buelga C, Sanjiv K, et al
    NEIL3 prevents senescence in hepatocellular carcinoma by repairing oxidative lesions at telomeres during mitosis.
    Cancer Res. 2021 May 27. pii: 0008-5472.CAN-20-1028.
    PubMed     Abstract available


  41. MA APY, Yeung CLS, Tey SK, Mao X, et al
    Suppression of ACADM-mediated fatty acid oxidation promotes hepatocellular carcinoma via aberrant Cav1/SREBP-1 signaling.
    Cancer Res. 2021 May 11. pii: 0008-5472.CAN-20-3944.
    PubMed     Abstract available


    April 2021
  42. LEUNG HW, Leung CO, Lau EY, Chung KPS, et al
    EPHB2 activates beta-catenin to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma.
    Cancer Res. 2021 Apr 26. pii: 0008-5472.CAN-21-0184.
    PubMed     Abstract available


  43. DU L, Li Y, Kang M, Feng M, et al
    USP48 is upregulated by Mettl14 to attenuate hepatocellular carcinoma via regulating SIRT6 stabilization.
    Cancer Res. 2021 Apr 26. pii: 0008-5472.CAN-20-4163.
    PubMed     Abstract available


  44. RICCIOTTI E, Wangensteen KJ, FitzGerald GA
    Aspirin in hepatocellular carcinoma.
    Cancer Res. 2021 Apr 23. pii: 0008-5472.CAN-21-0758.
    PubMed     Abstract available


  45. FUHRMAN BJ, Moore SC, Byrne C, Makhoul I, et al
    Association of the Age at Menarche with Site-Specific Cancer Risks in Pooled Data from Nine Cohorts.
    Cancer Res. 2021;81:2246-2255.
    PubMed     Abstract available


  46. BROADFIELD LA, Duarte JAG, Schmieder R, Broekaert D, et al
    Fat Induces Glucose Metabolism in Nontransformed Liver Cells and Promotes Liver Tumorigenesis.
    Cancer Res. 2021;81:1988-2001.
    PubMed     Abstract available


    February 2021
  47. ZHOU J, Li Q, Cao Y
    Spatiotemporal Heterogeneity Across Metastases and Organ-Specific Response Informs Drug Efficacy and Patient Survival in Colorectal Cancer.
    Cancer Res. 2021 Feb 15. pii: 0008-5472.CAN-20-3665.
    PubMed     Abstract available


  48. DAVENPORT ML, Echols JB, Silva AD, Anderson JC, et al
    miR-31 displays subtype specificity in lung cancer.
    Cancer Res. 2021 Feb 8. pii: 0008-5472.CAN-20-2769.
    PubMed     Abstract available


    January 2021
  49. YAMADA K, Oikawa T, Kizawa R, Motohashi S, et al
    Unconventional Secretion of PKCdelta Exerts Tumorigenic Function via Stimulation of ERK1/2 Signaling in Liver Cancer.
    Cancer Res. 2021;81:414-425.
    PubMed     Abstract available


  50. HONG SH, Son KH, Ha SY, Wee TI, et al
    Nucleoporin 210 Serves a Key Scaffold for SMARCB1 in Liver Cancer.
    Cancer Res. 2021;81:356-370.
    PubMed     Abstract available


  51. GENG Y, Fan J, Chen L, Zhang C, et al
    A Notch-Dependent Inflammatory Feedback Circuit between Macrophages and Cancer Cells Regulates Pancreatic Cancer Metastasis.
    Cancer Res. 2021;81:64-76.
    PubMed     Abstract available


  52. BATTISTELLI C, Garbo S, Riccioni V, Montaldo C, et al
    Design and Functional Validation of a Mutant Variant of the LncRNA HOTAIR to Counteract Snail Function in Epithelial-to-Mesenchymal Transition.
    Cancer Res. 2021;81:103-113.
    PubMed     Abstract available


    October 2020
  53. WILLS CA, Liu X, Chen L, Zhao Y, et al
    Chemotherapy-Induced Upregulation of Small Extracellular Vesicle-Associated PTX3 Accelerates Breast Cancer Metastasis.
    Cancer Res. 2020 Oct 28. pii: 0008-5472.CAN-20-1976.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: